logo BDSP

Base documentaire


  1. The economic costs of acute myeloid leukemia in Sweden.

    Article - En anglais

    The direct and indirect costs of acute myeloid leukemia were estimated for Sweden in 1989.

    The calculated total cost was SEK 460 million.

    Nearly half of the costs, or 1.7 million per patient diagnosed, were indirect costs due to premature mortality.

    Direct costs of relapses and indirect costs of mortality represent costs due to the absence of completely curable therapy.

    They also represent potential cost savings that could be obtained after introduction of new treatment options in the future.

    Mots-clés Pascal : Leucémie myéloïde, Analyse coût, Homme, Suède, Europe, Economie santé, Traitement, Hémopathie maligne, Myéloprolifératif syndrome

    Mots-clés Pascal anglais : Chronic myelocytic leukemia, Cost analysis, Human, Sweden, Europe, Health economy, Treatment, Malignant hemopathy, Myeloproliferative syndrome

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0094352

    Code Inist : 002B19B. Création : 09/06/1995.